Adebrelimab + Chemo with Radiation for Extensive-Stage SCLC
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer (cancer that has spread outside one lung or to other parts of the body).
- You must not have had any chemotherapy or other treatments specifically for this stage of cancer before.
- Your cancer must be measurable on scans, with no more than 5 spots (tumors) that have spread.
- You need to be in generally good health, able to walk and care for yourself (ECOG score 0-2), with a life expectancy of at least 3 months.
- Your major organs (heart, lungs, liver, kidneys, bone marrow) must be working well enough, based on blood tests and heart ultrasound.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
This trial tests a low dose of radiation to the chest followed by a combination of an immunotherapy drug (adebrelimab) and chemotherapy for extensive-stage small cell lung cancer. Afterward, you would continue taking adebrelimab alone as maintenance therapy.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation treatment for patients with advanced non-small cell lung cancer that cannot be surgically removed. The goal is to improve how well treatment works and help patients live longer.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and radiation therapy to see if it works better than standard treatment for people with extensive-stage small cell lung cancer who have not been treated before.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.